![]() |
|
|
Vol. 27, Issue 10, 1205-1213, October 1999
Research and Development, Nycomed Imaging AS, Oslo, Norway
Liposomes loaded with the nonionic iodinated contrast agent
iodixanol were injected i.v. into monkeys, rats, and dogs, and liver
samples were analyzed by HPLC and mass spectrometry. Two metabolites
(M1 and M2), with UV spectra identical to those of the iodixanol
isomers (exo and endo) and with a mass increase of 162 compared with
iodixanol, were detected. Incubations of iodixanol-liposomes or
iodixanol in rat liver homogenates resulted in large amounts of
iodixanol metabolites, whereas no metabolites were formed in other
organ or tissue homogenates. Four groups of unidentified HPLC peaks
were detected: M1 and M2 with a relative retention similar to the
metabolite peaks of the in vivo samples, and in addition the minor M3
and M4. UV spectrum analysis indicated that M1 and M3 were structurally
related to the iodixanol exo-isomer, whereas M2 and M4 were related to
the endo-isomer. Mass spectrometry techniques indicated that the
metabolites were conjugates containing one or two hexose residues,
which by carbohydrate analysis and experiments with concanavalin
A-Sepharose and
- and
-glucosidase were shown to be glucose
residues bound to iodixanol through
O-
1-glycoside-like linkages. Metabolites with similar
mass increments also were detected for several other nonionic contrast
agents after in vitro incubations in liver homogenates. In conclusion,
M1 and M3 are conjugates of the iodixanol exo-isomer with one and two
glucose adducts, respectively. M2 and M4 are similar conjugates of the
iodixanol endo-isomer. This is the first report on hepatic
biotransformation of this class of X-ray contrast agents.